This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

TRxADE HEALTH Beheer

Beheer criteriumcontroles 3/4

TRxADE HEALTH's CEO is Suren Ajjarapu, appointed in Jan 2014, has a tenure of 9.67 years. total yearly compensation is $414.23K, comprised of 85.5% salary and 14.5% bonuses, including company stock and options. directly owns 12.16% of the company’s shares, worth €1.06M. The average tenure of the management team and the board of directors is 9.3 years and 8.2 years respectively.

Belangrijke informatie

Suren Ajjarapu

Algemeen directeur

US$414.2k

Totale compensatie

Percentage CEO-salaris	85.5%
Dienstverband CEO	9.7yrs
Eigendom CEO	12.2%
Management gemiddelde ambtstermijn	9.3yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Suren Ajjarapu's beloning veranderd ten opzichte van TRxADE HEALTH's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$4m
Mar 31 2023	n/a	n/a	-US$3m
Dec 31 2022	US$414k	US$354k	-US$3m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$388k	US$372k	-US$5m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$667k	US$286k	-US$3m
Sep 30 2020	n/a	n/a	-US$719k
Jun 30 2020	n/a	n/a	-US$830k
Mar 31 2020	n/a	n/a	-US$229k
Dec 31 2019	US$750k	US$250k	-US$284k
Sep 30 2019	n/a	n/a	US$23k
Jun 30 2019	n/a	n/a	US$89k
Mar 31 2019	n/a	n/a	US$52k
Dec 31 2018	US$200k	US$200k	US$9k
Sep 30 2018	n/a	n/a	US$337k
Jun 30 2018	n/a	n/a	US$319k
Mar 31 2018	n/a	n/a	US$292k
Dec 31 2017	US$149k	US$149k	US$289k
Sep 30 2017	n/a	n/a	US$88k
Jun 30 2017	n/a	n/a	-US$284k
Mar 31 2017	n/a	n/a	-US$922k
Dec 31 2016	US$199k	US$149k	-US$1m

Compensatie versus markt: Suren's total compensation ($USD414.23K) is about average for companies of similar size in the German market ($USD418.12K).

Compensatie versus inkomsten: Suren's compensation has increased whilst the company is unprofitable.

CEO

Suren Ajjarapu (52 yo)

9.7yrs

Tenure

US$414,231

Compensatie

Mr. Surendra K. Ajjarapu, also known as Suren, serves as Chairman of the Board, Chief Executive Officer of PowerUp Acquisition Corp. since August 18, 2023. He serves as Chief Executive Officer and Chairman...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Surendra Ajjarapu	Founder	9.7yrs	US$414.23k	12.16% € 1.1m
Prashant Patel	Founder	9.7yrs	US$157.04k	11.11% € 970.2k
Ramesh Kenchappa	Chief Scientific Officer	9yrs	geen gegevens	geen gegevens
David Saslow	Inhouse Counsel	no data	geen gegevens	geen gegevens
Jariel Morales	Executive Vice President	6.4yrs	geen gegevens	geen gegevens

9.3yrs

Gemiddelde duur

Ervaren management: 4E40's management team is seasoned and experienced (9.3 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Surendra Ajjarapu	Founder	9.7yrs	US$414.23k	12.16% € 1.1m
Prashant Patel	Founder	9.7yrs	US$157.04k	11.11% € 970.2k
Michael Peterson	Independent Director	less than a year	US$96.25k	0% € 0
Candice Beaumont	Director	less than a year	geen gegevens	geen gegevens
A. Newell	Independent Director	less than a year	US$59.35k	0% € 0
Donald Anderson	Member of Advisory Board	8.2yrs	geen gegevens	geen gegevens
Donald Fell	Independent Director	9.7yrs	US$129.25k	0.39% € 34.4k

8.2yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: 4E40's board of directors are considered experienced (8.2 years average tenure).

This company is no longer active

TRxADE HEALTH Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH, INC Announces Board Changes

Less than half of directors are independent

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

Recent updates

Scienture Inc. acquired TRxADE HEALTH, Inc. (NasdaqCM:MEDS) in a reverse merger transaction in a transaction valued at $103 Million.

TRxADE HEALTH, INC. Announces Special Cash Dividend, Payable on or About July 24, 2024

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.061 loss per share (vs US$0.16 loss in 3Q 2021)

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.32 loss in 2Q 2021)

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2021)

No longer forecast to breakeven

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings released: US$0.65 loss per share (vs US$0.33 loss in FY 2020)

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

New 90-day high: €4.96

New 90-day low: €3.98

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: €4.18

New 90-day low - €4.76

Trxade Group, Inc. to Report Q2, 2020 Results on Jul 27, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd